⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22978713 | 1.00 | — | — | |
| SCHEMBL31013217 | 0.74 | — | — | |
| SCHEMBL22824181 | 0.74 | — | — | |
| SCHEMBL29480787 | 0.74 | — | — | |
| SCHEMBL1205413 | 0.74 | — | — | |
| SCHEMBL845963 | 0.74 | — | — | |
| SCHEMBL414351 | 0.74 | — | — | |
| SCHEMBL411439 | 0.74 | — | — | |
| SCHEMBL29737981 | 0.74 | — | — | |
| SCHEMBL30420491 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743078-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4562015-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025072395-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025015104-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2024026481-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-4271672-A1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-4247804-A1 | POLYHETEROCYCLIC GLP-1 R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2022109182-A9 | POLYHETEROCYCLIC GLP-1 R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022225941-A1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| EP-4013755-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| WO-2022109182-A1 | POLYHETEROCYCLIC GLP-1 R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |